Back to Newsroom

Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270

ROCKVILLE, Md., June 13, 2017 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a patent for VTS-270, a novel and well-characterized 2-hydroxypropyl-beta-cyclodextrin (HPβCD) product, under investigation as an intrathecally administered treatment for Niemann-Pick Disease Type C1 (NPC-1).